Compugen Ltd. (CGEN)
| Market Cap | 156.69M |
| Revenue (ttm) | 33.46M |
| Net Income (ttm) | -18.75M |
| Shares Out | 89.53M |
| EPS (ttm) | -0.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 600,588 |
| Open | 2.100 |
| Previous Close | 2.110 |
| Day's Range | 1.740 - 2.100 |
| 52-Week Range | 0.530 - 3.030 |
| Beta | 2.72 |
| Analysts | Strong Buy |
| Price Target | 7.33 (+321.26%) |
| Earnings Date | May 20, 2024 |
About CGEN
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic... [Read more]
Financial Performance
In 2023, Compugen's revenue was $33.46 million, an increase of 346.12% compared to the previous year's $7.50 million. Losses were -$18.75 million, -44.34% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for CGEN stock is "Strong Buy." The 12-month stock price forecast is $7.33, which is an increase of 321.26% from the latest price.
News
Compugen Reports First Quarter 2024 Results
Enrollment completed and on track to present data from COM701 + COM902 + pembrolizumab platinum resistant ovarian cancer study in Q4 2024 Data from COM701 + COM902 + pembrolizumab study in microsatell...
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
HOLON, Israel, May 16, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the...
Compugen Appoints David Silberman as Chief Financial Officer
HOLON, Israel , May 15, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced th...
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
HOLON, ISRAEL , May 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced tha...
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
HOLON, Israel , April 25, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced...
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
HOLON, Israel , April 10, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...
Compugen to Participate in Two Upcoming Investor Conferences
HOLON, Israel , April 3, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced t...
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
HOLON, Israel , March 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
HOLON, Israel , March 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...
Compugen Reports Fourth Quarter and Full Year 2023 Results
Partnership with Gilead on preclinical immuno-oncology program further validates Compugen's computational discovery, research, and development capabilities Catalyst rich 2024 expected with multiple da...
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
HOLON, Israel , Feb. 26, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced t...
Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024
HOLON, Israel , Feb. 20. 2024 /PRNewswire/ -- Compugen Ltd.
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
HOLON, Israel , Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
HOLON, Israel , Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced th...
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
HOLON, Israel , Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today th...
Compugen stock rockets on anti-tumor drug deal with Gilead
Compugen Ltd.'s stock CGEN, -3.36% was up by 113% in premarket trading on Tuesday after the company said it agreed to sell exclusive rights to Gilead Sciences Inc. GILD, -1.03% for later stage develop...
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Dosing of first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody, will trigger $10 million milestone payment from AstraZeneca HOLON, Israel , Dec. 19, 2023 /PRNewswire/ -- C...
Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology
Conference call today, December 19, 2023, 8:30 AM ET to discuss the license agreement HOLON, Israel , Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer im...
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
FOSTER CITY, Calif. & HOLON, Israel--(BUSINESS WIRE)--Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program.
Compugen Reports Third Quarter 2023 Results
Rilvegostomig, AstraZeneca's (LSE/STO/Nasdaq: AZN) PD-1/TIGIT bi-specific derived from Compugen's COM902, has progressed into Phase 3 as adjuvant therapy for biliary tract cancer after resection in co...
Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy
COM701 + nivolumab + BMS-986207 (anti-TIGIT) resulted in clinically meaningful durable partial responses > 16 months in platinum resistant ovarian cancer patients COM701 dual and triple combinations m...
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
HOLON, Israel , Nov. 3, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today th...
Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer
COM503, a potential first-in-class, high affinity anti-IL18 binding protein antibody frees endogenous IL-18 to inhibit cancer growth Anti-IL-18BP antibody immune modulation is confined to the tumor si...
Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023
HOLON, Israel , Oct. 24, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, ...
These Israeli pharmaceutical stocks are down in the wake of Hamas attack
Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.